Dr. Barrett joined venture capital firm New Enterprise Associates (NEA) in 2001 as a General Partner. He specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices and specialty pharmaceutical companies. Present board memberships in addition to GlycoMimetics include Clovis Oncology, Proteostasis Therapeutics, and Senseonics. Prior to NEA, Dr. Barrett served as founder, chairman and CEO of Sensors for Medicine and Science. He has also led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, Inc., President and CEO of Life Technologies and President and CEO of Bethesda Research Labs. He also worked in various divisions of SmithKline. Dr. Barrett holds a Ph.D. in biochemistry at the University of Tennessee, an M.B.A. from the University of Santa Clara, and a B.S. in Chemistry from Boston College.
Ms. Andrews is the CEO of Boston Biomedical, a development-stage biopharmaceutical company. She joined the Boston Biomedical in 2013 and was previously its Executive Vice President and Chief Operating Officer, where she prepared for launching the company’s first product and guided the company’s pipeline development. Prior to that, she was Executive Vice President and Chief Commercial Officer at Incyte, leading commercial operations for that company’s launch of first-in-class, first-in-disease oncology product Jakafi®. Her additional experience includes leadership positions at Pfizer, where her final role was Vice President and General Manager of the US Oncology Business Unit, and at Marine Midland/HSBC, where she was Vice President in corporate finance. Ms. Andrews received her M.B.A. from the University of Michigan and her B.A. from Brown University.
Dr. Goldberg is a consultant to several biotechnology companies. Previously he served as Executive Vice President for Medical and Regulatory strategy and as the Senior Vice President of Medical and Regulatory Affairs at Synageva BioPharma Corp. Dr. Goldberg also worked in a variety of senior management positions at Genzyme Corporation, including as Senior Vice President and Therapeutic Group Head for Oncology and Personalized Genetic Health Clinical Development. Prior to Genzyme, he was a staff physician at Brigham and Women’s Hospital and Dana Farber Cancer Institute, where he still holds appointments. He was an associate professor of medicine at Harvard Medical School from 1996 to 2018 and he now serves as senior lecturer. Dr. Goldberg is a board-certified medical oncologist and hematologist and has more than 50 published papers. He currently serves on the Board of Directors of ImmunoGen, Inc., Blueprint Medicines, Idera Pharmaceuticals and Audentes Therapeutics. He holds an A.B. from Harvard College and an M.D. from Harvard Medical School.
Scott Jackson served as Celator CEO and as a member of the Board of Directors from April 2008 until July 2016, when the company was acquired by Jazz Pharmaceuticals plc. Under Mr. Jackson's leadership, Celator successfully developed Vyxeos® for treatment of newly diagnosed AML patients. He has more than 25 years of experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing and commercial development at Eli Lilly & Co., SmithKline Beecham, ImClone Systems Inc., Centocor Inc., a division of Johnson & Johnson, Eximias Pharmaceutical and YM BioSciences. Mr. Jackson holds a B.S. in pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from the University of Notre Dame. He presently serves on the Board of Directors of MacroGenics, Inc. and the Board of Trustees of the Eastern Pennsylvania Chapter of The Leukemia and Lymphoma Society®.
Mr. Junius has been a director of GlycoMimetics, Inc. since March 2016. He also serves as director at IDEXX Laboratories, Inc. He previously served as President and CEO of ImmunoGen from 2009 until his retirement in May 2016, preceded by several executive roles including President, COO, Executive Vice President and CFO. Before joining ImmunoGen, Mr. Junius was Executive Vice President and CFO of New England Business Service, Inc. until its acquisition by Deluxe Corporation in 2004. Mr. Junius holds an undergraduate degree in Political Science from Boston College and a Master’s in Management from Northwestern University’s Kellogg School of Management.
Mrs. King is co-founder and CEO of GlycoMimetics, Inc. (GMI). Before founding GMI, she was an Executive in Residence at New Enterprise Associates (NEA), one of the nation’s leading venture capital firms. Mrs. King came to NEA after serving as a senior vice president of Novartis Corporation. Before joining Novartis, Mrs. King spent 10 years with Genetic Therapy, Inc. through the company’s early stage, initial public offering and eventual sale to Novartis. After the sale to Novartis, she was named CEO and ran the company as a wholly-owned subsidiary of Novartis. Mrs. King also worked previously at ALZA Corporation in Palo Alto, CA and at Bain & Company in Boston. Mrs. King is the past Chair of the Board as well as past of the Chair Emerging Companies Governing Board of the Biotechnology Innovation Organization (“BIO”); she continues to serve on BIO’s executive committee. She also served as Chair of the Maryland Life Sciences Advisory Board under former Governor Martin O’Malley. She now serves on the board of the University of Maryland BioPark. She received her B.A. degree from Dartmouth College and her M.B.A. from Harvard Business School.
Dr. Koenig has been President, CEO and a director of MacroGenics, Inc. since September 2001 and was one of the company’s co-founders. Previously, Dr. Koenig served as Senior Vice President of Research at MedImmune, where he participated in the selection and maturation of its product pipeline. He also worked at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS. Dr. Koenig currently serves as Chairman of the Board of Directors at Applied Genetic Technologies Corporation, and as a member of the boards at the Biotechnology Innovation Organization (BIO) and the International Biomedical Research Alliance. He serves as co-chair of the Scientific Advisory Board of the Institute for Bioscience and Biotechnology Research (IBBR) at the University of Maryland. Dr. Koenig received his A.B. and Ph.D. from Cornell University and his M.D. from the University of Texas Health Science Center in Houston.
Senior Vice-President, Research and Chief Scientific Officer
Dr. Magnani is co-founder and CSO of GlycoMimetics, Inc (GMI). Prior to co-founding GMI, Dr. Magnani founded and led a predecessor company, GlycoTech Corporation, as its President and CEO. Previously, he helped co-found the U.S. subsidiary of BioCarb and became its international Vice President of Research. Dr. Magnani received his Ph.D. from Princeton University and then joined the Laboratory of Biological Pharmacology of the National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases (NIADDK) of the National Institutes of Health (NIH). He remained at the NIH for 10 years, finally serving as a tenured research chemist. Dr. Magnani is an expert in glycobiology, having discovered and characterized many carbohydrate tumor antigens, such as the FDA-approved cancer diagnostic, CA19-9. He also developed fundamental technology for the identification of functional carbohydrate epitopes. Dr. Magnani is the discoverer of Sialyl Lea and its functions. He was the first to identify the binding domain to the selectins common to both Sialyl Lea and Sialyl Lex and used this information to develop potent selectin antagonists as drug candidates now in clinical trials. He is the recipient of the 2015 President’s Innovation Award from the Society of Glycobiology, has authored over 100 scientific publications and is an inventor on more than 90 issued patents.
Mr. Pearson is the former Chief Financial Officer and Executive Vice President for TESARO, Inc., a publicly held oncology-focused biopharmaceutical company. Prior to that, he served as Executive Vice President, Chief Financial Officer and Treasurer at Catalyst Health Solutions, a publicly held pharmacy benefit manager with over $5 billion in revenues. Mr. Pearson led the company’s financial activities, including performance management, investor relations, SEC compliance, capital strategy and planning, until the company was acquired by SXC Health Solutions (now Catamaran Corporation) in 2012. Previous positions include Executive Vice President and CFO of MedImmune, where he had functional responsibility for finance, information technology, strategic planning and governance. Mr. Pearson, a CPA, holds B.S. degrees in Business Administration from the University of Delaware and in Accounting from the University of Maryland University College, as well as an M.S. in Finance from Loyola University.